Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine. Chalkias S, Pragalos A, Akinsola A, Berman G, et al. J Infect Dis 2025 Jan 10:jiaf022. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chalkias S, Pragalos A, Akinsola A, Berman G, et al. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine. J Infect Dis 2025 Jan 10:jiaf022. doi: 10.1093.
PMID: 39792478